Related Experiment Video
Updated: Aug 6, 2026
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Clinical association between myelodysplastic syndrome and de novo bone metastasis in urothelial carcinoma
Zhilong Zestel Shen1, Gan Xu1,2, Hao Zhang1
1Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, #415 Fengyang Road, Shanghai, 200003, China.
Aim:
To assess the association between myelodysplastic syndrome and de novo bone metastasis of urothelial carcinoma.
Method:
A cohort of 145,719 patients with MDS and/or UTCA included from the surveillance, epidemiology, and end results (SEER) database was conducted to assess the risk of de novo bone metastasis of UTCA (DNBM-UTCA) in patients with previously diagnosed myelodysplastic syndrome (PD-MDS). The odds ratio for developing DNBM-UTCA between MDS and non-MDS patients was estimated. Weibull accelerated failure time model was applied to evaluate the survival outcomes of patients with UTCA.
Results:
Our findings suggest that PD-MDS is a powerful risk factor for DNBM-UTCA (adjusted odds ratio, 6.428; 95% CI, 1.866-16.497; p < 0.001) and a poor prognostic factor on survival (adjusted survival time ratio, 0.485; CI, 0.338-0.695; p < 0.001).
Conclusion:
Our findings suggest that PD-MDS was associated with higher odds of DNBM-UTCA and poorer survival outcomes, which may warrant additional clinical attention during treatment decision-making. However, these findings should be considered hypothesis-generating rather than causal. Further prospective studies and mechanistic investigations are needed to better clarify the biological basis underlying the observed association between PD-MDS and bone metastasis in UTCA.
